Assessment of Isoprostanes in Human Plasma: Technical Considerations and the Use of Mass Spectrometry.
Yiu Yiu LeeJean-Marie GalanoCamille OgerClaire VigorReversat GuillaumeJérôme RoyJean-Yves Le GuennecThierry DurandJetty Chung-Yung LeePublished in: Lipids (2016)
Oxygenated lipid mediators released from non-enzymatic peroxidation of polyunsaturated fatty acids (PUFA) are known to have functional roles in humans. Notably, among these lipid mediators, isoprostanes molecules are robust biomarkers of oxidative stress but those from n-3 PUFA are also bioactive molecules. In order to identify and assess the isoprostanes, the use of mass spectrometry (MS) for analysis is preferable and has been used for over two decades. Gas chromatography (GC) is commonly coupled to the MS to separate the derivatized isoprostanes of interest in biological samples. In order to increase the accuracy of the analytical performance, GC-MS/MS was also applied. Lately, MS or MS/MS has been coupled with high-performance liquid chromatography to assess multiple isoprostane molecules in a single biological sample without derivatization process. However, there are limitations for the use of LC-MS/MS in the measurement of plasma isoprostanes, which will be discussed in this review.
Keyphrases
- mass spectrometry
- gas chromatography
- high performance liquid chromatography
- liquid chromatography
- tandem mass spectrometry
- ms ms
- ultra high performance liquid chromatography
- high resolution mass spectrometry
- gas chromatography mass spectrometry
- oxidative stress
- simultaneous determination
- solid phase extraction
- high resolution
- capillary electrophoresis
- liquid chromatography tandem mass spectrometry
- ischemia reperfusion injury
- induced apoptosis
- nitric oxide
- dna damage
- heat shock